What is EMBC's 12-month stock price target?

Embecta Corp. (EMBC) carries a 12-month consensus base price target of $6.47 (+4.5% from $6.19), with a bull-case target of $15.66 and a bear-case floor of $5.05.

Stock Ratings / Health Care / EMBC / forecast

MOBI (50) CLPT (19) OFIX (42) SI (44) ⌘ Pro Terminal →

Embecta Corp. (EMBC) 12-Month Stock Forecast & Price Target Cone

Q: Is EMBC stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates EMBC C+ (Hold — HOLD) with an RQD Confidence score of 68/100.

$6.19 -0.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.17

Embecta Corp. (EMBC) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $354.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on EMBC Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is EMBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Embecta Corp. (NASDAQ: EMBC) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 68/100 at a spot price of $6.19 (-0.96% 1D, market cap $354.1M). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, EMBC ranks #96 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does EMBC compare to MOBI and CLPT in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), EMBC carries a Roarable C+ (68/100 RQD), trailing P/E of 3.9x, gross margin of 62.6%, and ROIC of 35.5%. By comparison, MOBI (Mobia Medical Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $352.2M) and CLPT (ClearPoint Neuro Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $342.0M). Among the 5-stock peer group, EMBC leads on earnings multiple (3.9x) while EMBC leads on capital efficiency (35.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for EMBC?

▼

Per EMBC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001872789), Embecta Corp. generated $1.08B in revenue (-3.8% YoY), $95.4M in net income, and $182.4M in free cash flow against $1.06B in total assets and $1.35B in total debt. Key quantitative strengths: Strong cash generator (63% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.17 (-0.36%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 16.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 68/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.8% avg 90D alpha vs SPY • 56.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

2-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+4.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EMBC)Realized 20D OHLCV Swing Band: ±9.6%

Deterministic 5-Pillar Attribution (68/100 Composite)

🔍 WHY EMBC SCORES 68/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (28% of score)

SEC XBRL FY 2025 (10-K): 16.9% FCF Margin ($182.4M FCF) & 62.6% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$6.20+3.5% Next Q

Q2 (-2Q)

Grade B$6.42+2% Next Q

Q3 (-1Q)

Grade B$6.55-5.5% Next Q

Current

Grade C+$6.19+1.8% Hist 90D α

Trajectory: B+ (76) → C+ (68)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the EMBC Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 68/100 (C+) score, EMBC faces multiple-compression risk if 3.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 60.1% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.79) or 200D SMA ($6.38) invalidates the momentum regime and cuts Target Base ($6.47) toward Bear Floor ($5.05).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $EMBC• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “EMBC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”

YES 68%NO 32%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your EMBC Position Size: $10,000

Shares at $6.19: 1615.5 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $5.05

$8,158

$-1,842 (-18.4%)

12M Consensus BaseTarget $6.47

$10,452

+$452 (+4.5%)

12M Bull Case BreakoutTarget $15.66

$25,299

+$15,299 (+153.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$7	74%	A
Goldman SachsSector Coverage Lead	BUY	$15	69%	B
JP MorganUS Large-Cap Research	HOLD	$6	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (EMBC Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

EMBC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.08%▲ ASCENDING CHANNEL

2026-11-03O $6.56H $6.56L $6.19C $6.19VOL 831.1K

RES: $7.14SUP: $3.73SMA50: $5.79SMA200: $6.38

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

EMBC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 EMBC Butterfly Map → + Track EMBC →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

-15.0%/yr Implied 5Y Growth

vs. -3.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on EMBC today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for EMBC. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for EMBC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EMBC)

Health Care Rank #96 of 1016 ⚔️ MOBI vs EMBC Full Matrix →

1. Head-to-Head Health Care Peer Comparison (EMBC vs. MOBI, CLPT, OFIX, SI)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Embecta Corp. (EMBC) ranks #96 by composite RQD confidence (68/100, grade C+) and #494 by equity capitalization ($354.1M). Within this direct 5-issuer industry benchmark cohort, EMBC leads on earnings valuation at 3.9x trailing P/E, while EMBC leads on capital efficiency and profitability with 35.5% ROIC and 62.6% gross margin. EMBC currently leads its immediate peer cohort in composite quantitative strength at 68/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
EMBC ACTIVE Embecta Corp.	C+	68/100	3.9x	62.6%	35.5%	-0.96%	$354.1M	Benchmark Subject
MOBI Mobia Medical Inc.	D	50/100	—	—	—	-4.82%	$352.2M	/mobi-vs-embc →
CLPT ClearPoint Neuro Inc.	E	19/100	—	61.4%	-35.0%	-6.75%	$342.0M	/clpt-vs-embc →
OFIX Orthofix Medical Inc.	D-	42/100	—	68.8%	-12.2%	-3.53%	$369.4M	/ofix-vs-embc →
SI Shoulder Innovations Inc.	D	44/100	—	76.5%	-16.1%	+0.99%	$398.3M	/si-vs-embc →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001872789

In its most recent audited fiscal period (FY2025, filed 2025-09-30), Embecta Corp. (EMBC) reported GAAP revenue of $1.08B (-3.8% vs. FY2024 revenue of $1.12B , and -3.6% cumulative change since FY2023) , GAAP net income of $95.4M, operating cash flow of $191.7M, and free cash flow of $182.4M (+816.6% YoY). On the balance sheet, EMBC closed FY2025 with $1.06B in total assets against $1.35B in total debt (Altman Z-Score: N/A, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-09-30	$1.08B	$95.4M	$191.7M	$182.4M	$1.06B	$1.35B
FY2024 (FY)	2024-09-30	$1.12B	$78.3M	$35.7M	$19.9M	$1.15B	$1.53B
FY2023 (FY)	2023-09-30	$1.12B	$70.4M	$67.7M	$67.7M	—	—

3. EMBC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is EMBC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does EMBC compare to MOBI and CLPT in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for EMBC?

Where is EMBC trading relative to its 50-day, 200-day, and 52-week technical levels?

EMBC last traded at $6.19 (-0.96% on volume of 658,267 shares), positioning the stock +6.91% above its 50-day simple moving average ($5.79) and -2.98% below its 200-day simple moving average ($6.38). Across its 52-week range of $2.77 to $14.91, EMBC sits at the 28.2% percentile with a 14-day RSI of 51.2 (NEUTRAL RANGE) and an implied next-earnings move of ±9.6% ($5.60 to $6.78).

Direct Sub-Reports: EMBC RQD Cockpit EMBC 12M Forecast EMBC Earnings & Move EMBC Dividends & DRIP EMBC Insiders & 13F EMBC Whale Options EMBC Profit Sankey EMBC News & Why

ROARABLE RATING BRIEF • RQD 68/100 (C+) ✓ SEC XBRL & RQD VERIFIED

EMBC — Embecta Corp.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-09-30

1. Roarable Rating Brief: What This Means to a Prospective Investor

Embecta Corp. (EMBC) earns a live Roarable RQD composite score of 68/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $6.19 (-0.96% 1D, market capitalization $354.1M).

Fundamental Cash Engine (19/20): Anchored by return on invested capital (ROIC) of 35.5%, gross margin of 62.6%, operating margin of 22.4%, and free cash flow yield of —.
Whale 13F & Options Flow (8/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (17/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 7/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Embecta Corp. (EMBC) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. Its market capitalization is $0.4B. Per the market data, its gross margin is 62.6%, operating margin 22.4%, and net margin 8.8%.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-09-30), Embecta Corp. (EMBC) reported $1.08B in annual revenue (up from $1.12B in FY2024, -3.8% YoY) and $95.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.12B revenue, $70.4M net income) through FY2025, EMBC scaled operating cash flow to $191.7M and free cash flow to $182.4M, backed by $1.06B in total assets against $1.35B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (C+ • RQD 68/100): Strong cash generator (63% profit margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 19/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $2.77 – $14.91 52-week range.
🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh 3.9x trailing P/E and 6.1x EV/EBITDA against 22.4% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply chain: NONE; butterfly links: none; proprietary signals: none.

Key Question #1: Can EMBC sustain or expand its 22.4% operating margin and 35.5% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.08B and free cash flow of $182.4M, how will capital allocation balance growth reinvestment against $1.35B in total debt?
Key Question #3: How sensitive is EMBC's 3.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

EMBC Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Embecta Corp. (EMBC) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to EMBC Debate Forum (3) ↓

🟡 MARKET WIRE Stocktwits • 20h ago

EMBC: Embecta Corp Latest Stock Price, Analysis, News and Trading Ideas

Stocktwits report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Yahoo Finance • 23h ago

What Embecta Bears Saw Before A 55% Drop

Yahoo Finance report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 1d ago

Analysts Offer Insights on Healthcare Companies: Embecta Corporation (EMBC) and Airsculpt Technologies (AIRS)

The Globe and Mail report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The National Law Review • 1d ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Embecta Corp. (EMBC) And Encourages Stockholders to Connect

The National Law Review report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE kalkine.ca • 1d ago

Why Is Embecta (NASDAQ:EMBC) Up 6.86% on Light Volume With No Catalyst Found?

kalkine.ca report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 1d ago

Did Embecta's 52% Fall Catch You Out? What Investors Missed

Simply Wall St report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Embecta Q3 Earnings Call Highlights

TradingView report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

How Embecta Corp. (EMBC) Affects Rotational Strategy Timing

Stock Traders Daily report covering Embecta Corp. (EMBC) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

EMBC Bull vs. Bear Conversation Board — What's Your Call at $6.19?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EMBC 🐻 33% BEARISH CONVICTION

MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $7.56 (+21.0%)

📌 Pinned Debate

ROIC of 35.5% and FY 2025 operating income up to $242.1M from $166.8M point to strong cash-generation economics.

ROIC of 35.5% and FY 2025 operating income up to $242.1M from $166.8M point to strong cash-generation economics.. When you look under the hood at EMBC, Fundamental Cash Engine is 19/20 with 62.6% gross margins and 35.5% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (8/20) has been quietly accumulating below $14.91. My 12M target is $7.56.

EarningsSniper 🐂 BULL

@FadeTheHype Shorting a 8/20 institutional whale-flow stock at $6.25 is dangerous when funds are rotating into Health Care.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $4.75 (-24.0%)

Spot @ $6.25

A law-firm investigation notice and a 52–55% decline in the news wire, alongside $1.35B of debt and a 0% FCF yield, raise open questi

A law-firm investigation notice and a 52–55% decline in the news wire, alongside $1.35B of debt and a 0% FCF yield, raise open questions about the stock's risk profile.. Look at the math on EMBC: paying 3.9x trailing P/E for 35.5% ROIC and 22.4% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $5.50 before getting long.